Evidence map›Paper›PMID 41497071›Full record

ArticleAnnals of medicine and surgery (2012)2026

Echocardiographic and platelet markers of cardiovascular strain in sickle cell disease with superimposed preeclampsia: a perspective.

Emmanuel Ifeanyi Obeagu

Abstract read
In one paragraph

Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Emmanuel Ifeanyi ObeaguDepartment of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe.ORCID https://orcid.org/0000-0002-4538-0161

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sickle cell disease (SCD) and preeclampsia (PE) are both conditions associated with significant vascular dysfunction and increased cardiovascular risk, particularly during pregnancy. When PE is superimposed on SCD, the compounded pathophysiological effects exacerbate endothelial damage, inflammation, and hemodynamic stress, posing substantial risks to maternal and fetal health. Echocardiography offers a valuable non-invasive approach to assess cardiac function and detect subclinical cardiovascular alterations in pregnant women with SCD complicated by PE. Key echocardiographic markers, including left ventricular diastolic dysfunction, pulmonary hypertension, and right ventricular impairment, provide insight into the extent of cardiovascular compromise. Concurrently, platelet activation markers such as mean platelet volume and surface expression of adhesion molecules reflect a heightened pro-thrombotic state that contributes to vascular injury and disease progression. Integrating echocardiographic findings with platelet biomarkers may enhance risk stratification and guide targeted interventions to mitigate cardiovascular complications in this high-risk population. Further research is needed to establish standardized protocols and explore therapeutic avenues aimed at reducing maternal morbidity and improving pregnancy outcomes in women with SCD and superimposed PE.

Indexed as

cardiovascular strainechocardiographyplatelet activationpreeclampsiasickle cell disease

Identifiers

PMID41497071
PMCPMC12768150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.